Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition

Lung Cancer
15/05/2020

de Silva M, et al. Ann Transl Med 2020.

NO ABSTRACT